Action

mutant EGFR

Alt Name

Approval Jurisdiction

2018 FDA 2019 EMA

Approved for clinical use

NSCLC with EGFR mutations

Brutto

CAS

1110813-31-4

Commercial Vendor

Pfizer

Compound Image

Dacomitinib.png

Compound name

Dacomitinib

InChI

InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

InChI Key

LVXJQMNHJWSHET-AATRIKPKSA-N

MW

469.90

PubChem CID

11511120

Reference

Reference 2

SMILES

COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4

Approved Drug List

1